Your browser doesn't support javascript.
loading
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition.
Coats, Josh T; Tauro, Sudhir; Sutherland, Calum.
  • Coats JT; Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
  • Tauro S; Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
  • Sutherland C; Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. c.d.sutherland@dundee.ac.uk.
Cell Commun Signal ; 21(1): 131, 2023 06 14.
Article en En | MEDLINE | ID: mdl-37316860
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Glucógeno Sintasa Quinasa 3 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Glucógeno Sintasa Quinasa 3 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article